News

Information about Dr. David Shulkin and the Patient Safety Officer Society

Each month, showcasing innovative people, organizations, or ideas!This month, a new professional society launches?interview withDavid Shulkin, MD, president of the Patient Safety Officer Society

Tegaserod maleate (Zelnorm) is the first selective partial 5-HT4 agonist approved by FDA for the short-term treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is constipation. To help you prepare for P & T Committee review, this article presents tegaserod?s chemistry and pharmacology, pharmacokinetics, clinical trial results, adverse effects profile, dosing information, cost, and the author?s opinion on its place in therapy.

With enoxaparin?s recent labeling change regarding its use in patients with prosthetic valves, clinicians may have several questions about appropriate anticoagulant selection. Specifically, what evidence prompted the labeling change, which patients are affected, what are the options and limitations for bridging patients, what?s the evidence supporting the role of low molecular weight heparins (LMWHs) in bridge therapy, and how can liability be limited should clinicians choose to use LMWH therapy? The authors of this commentary offer their insight on these issues.

Sisters of Mercy CEO Ron Ashworth cultivates an environment of personalas well as clinical service

Go beyond traditional medical coverage and offer your members services that save time, cost and effort

Ranked by total nursing homes owned and leased by these chains, Dec. 2001

The biggest challenge for consumer-driven plans is keeping members aware of healthcare costs.

Sisters of Mercy CEO Ron Ashworth optimizes his resources by centralizing IT

Staying healthy on the job is clearly beneficial to all. Learn how Kawasaki puts the power of wellness right in its employees& hands.

In late May, voriconazole (Vfend) received approval for the treatment of invasive aspergillosis and as salvage therapy for treatment of Scedosporium apiospermum and Fusarium infections. In addition to these infections, voriconazole has excellent invitro activity against both Candida and Aspergillus species, including good activity against fluconazole- and itraconazole-resistant species. This Focus article reviews the antifungal's pharmacology, pharmacokinetics, efficacy in clinical trials, safety, dosing, price, and place in therapy.

Effective decision-making in benefit management requires an understanding of the economic burden of an illness - in this case, the economic burden and treatment of alcoholism. This article provides an understanding of the true costs of the disease, what has been found to be effective in its treatment, and what treatments may lessen the economic burden of the disease.

Finding optional ways to manage patients with chronic obstructive pulmonary disease (COPD) - the fourth leading cause of death in the US became a priority for this large mid-western collaborative of health care organizations. This this end, a guideline was developed to help clinicians identify, evaluate and manage COPD. This article provides an overview of the guideline development process and implementation approach, key guideline components, and the step-by-step pharmacologic treatment strategy.

Ruling shows that external review remains viable option for patients

HMOs challenge Kentucky law that prevents plans from limiting providernetworks

Irene Brewster*, a 31-year-old mother of two who was in her 31st week of pregnancy, woke up one morning and noticed that her calf was abnormally swollen. After a call to her obstetrician, who was out of town, Brewster rounded up her children and drove to the hospital.

It was lightning quick, as acquisitions go. From the first announcement to the final approval, WellPoint Health Networks rolled RightCHOICE Managed Care's 2.8 million members into its portfolio in just three months.

People always experience a certain amount of anxiety when adopting a new technology. When implementing that change costs tens of millions of dollars, however, it could become downright nerve-wracking.

by degree of integration and performance level, April 2002

Consortiums, Web visits and online management help payers overcome reluctance to increase online care

HCA joins Leapfrog, MBGH says 30% health care costs unnecessary, Rush Prudential v. Moran with ERISA, BCBSM compares prices of brand name drugs with generics, Kaiser study on state-by-state prescription drug cost

Does a disabled employee have the right to put his health at risk on the job? Here&s the gist of the Supreme Court&s reasoning on that question.

Just before leaving Washington for the Memorial Day recess in May, Congress approved legislation to enhance the ability of hospitals and public health agencies to respond to bioterrorist threats.

Three case-controlled studies published in the Archives of Internal Medicineshow naproxen sodium has cardioprotective effects that other NSAIDs don't.An accompanying editorial says that no evidence indicates that the COX-2inhibitor rofecoxib increases (or decreases) MI risk. It simply fell victimto being compared with the only NSAID (ie, naproxen) shown to have a cardioprotectivebenefit. (None of these new studies directly compared non-naproxen NSAIDswith COX-2 inhibitors.)

Pipeline Preview as reported July 1, 2002

Eplerenone, a selective aldosterone inhibitor in phase III clinical trials,is an effective agent for reducing blood pressure in a variety of patientswith hypertension, including African-Americans, said presenters at the 17thannual scientific meeting of the American Society of Hypertension in NewYork City.

Administrative databases are a potentially useful source of data for conducting retrospective studies. Information in such a database can be used to evaluate the effects of organizational policy changes, new programs, or pharmaceutical therapies. This month?s column reviews the six essential steps required for conducting a simple database analysis. An example involving sepsis is used to further illustrate key points.

Alefacept (Amevive) is the first immunosuppressive agent directed specifically at inhibiting the activation of, and possibly killing, T cells, which are involved in the cascade of events leading to psoriatic plaque formation and inflammation. In May, an FDA advisory committee recommended alefacept for approval as a first-line therapy against moderate to severe plaque psoriasis. The authors of this Focus article review the clinical characteristics of alefacept as well as make comparisons with other systemic drugs currently used to treat chronic psoriasis and the likely biologic competitors etanercept and infliximab.